Bempedoic Acid recalls

The FDA has published 2 recalls involving Bempedoic Acid since 2023. The latest was reported on 24 Apr 2024. Most were for potency & assay. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.

Total recalls2since 2023

Last 12 months0reported

Class I00% of total

Ongoing0latest 24 Apr 2024

Recalls per month, last 24 months

click a bar for that month

0Nov '24 0 0 0Feb 0 0 0May 0 0 0Aug 0 0 0Nov 0 0 0Feb 0 0 0May 0 0 0Aug 0 0

Severity split

Class I 0 0%Class II 0 0%Class III 2 100%

Why bempedoic acid is recalled

Potency & Assay2100%

Companies

Esperion2100%

By year

2024150%
2023150%

All bempedoic acid recalls, newest first

2 total

Reported	Class	Recall	Company	Reason	Where
24 Apr 2024Drug	CLASS III	Nexlizet (bempedoic acid and ezetimibe) tablets, 180 mg/10 mg recalledNexlizet	Esperion	Potency & Assay	Nationwide
13 Sep 2023Drug	CLASS III	Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg recalled by EsperionNexlizet	Esperion	Potency & Assay	Nationwide

Should you stop taking Bempedoic Acid?

Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.